EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expression of Cancer‐Testis Antigens MAGE ‐ A1 , MAGE ‐ A4 , NY ‐ ESO ‐1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China

Anni Chen, Yuling Qiu, Ying-Tzu Yen, Chun Wang, Xiaolu Wang, Chunhua Li, Zijian Wei, Lin Li, Lixia Yu, Fangcen Liu, Rutian Li iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70750 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Anni Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing University of Chinese Medicine, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Bone Neoplasms, Sarcoma, Neoplasm Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth project of Nanjing Medical Science and Technology Development Fund, Project supported by the Young Scientists Fund of the National Natural Science Foundation of China, Science Fund for Distinguished Young Scholars of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Sarcomas are a heterogeneous group of malignancies, low disease‐control levels and the limited durability of responses have prompted the exploration of various novel immunotherapeutic approaches. To preliminarily explore the feasibility of cancer vaccines based on cancer testis antigen in the immunotherapy of sarcomas, we investigate the expression of Cancer/Testis Antigens (CTA) MAGE‐A4, PRAME, MAGE‐A1, KK‐LC‐1, and NY‐ESO‐1 in bone and soft tissue sarcomas, with the aim of assessing their potential for use in sarcoma immunotherapy and determining their expression levels in different subtypes. Methods and Results We employed immunohistochemistry and multiplex immunostaining microarrays (MI chips) to assess the expression of MAGE‐A4, PRAME, MAGE‐A1, KK‐LC‐1, and NY‐ESO‐1 in 21 cases of undifferentiated pleomorphic sarcoma (UPS), 26 cases of smooth muscle sarcoma, 28 cases of liposarcoma, 40 cases of osteosarcoma (OS), and 13 cases of chondrosarcoma. MAGE‐A1 showed the highest expression in osteosarcoma (32.50%), while it was lower in liposarcoma and undifferentiated pleomorphic sarcoma (10.71% and 10.00%) and undetectable in chondrosarcoma. MAGE‐A4 expression was elevated in osteosarcoma and undifferentiated pleomorphic sarcoma (40.00% and 33.00%), but lower in liposarcoma and smooth muscle sarcoma (17.00% and 33.00%). NY‐ESO‐1 expression was relatively low across all sarcoma subtypes. PRAME expression was highest in undifferentiated pleomorphic sarcoma (47.62%) and low in chondrosarcoma (7.69%). None of the sarcomas expressed KK‐LC‐1. Additionally, while there was no statistically significant correlation between CTA expression and patient age or gender, some differences related to age and gender were observed.

Conclusions

CTA expression in bone and soft tissue sarcomas was correlated with both CTA type and sarcoma subtype, showing relatively high levels of expression in undifferentiated pleomorphic sarcoma (UPS) and osteosarcoma (OS). The poly‐expression of MAGE‐A4, PRAME, and MAGE‐A1 across all subtypes suggests that these antigens may serve as potential targets for sarcoma‐specific immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmBone NeoplasmsSarcomaNeoplasm ProteinsMembrane ProteinsMelanoma-Specific AntigensSoft Tissue NeoplasmsHumansMaleFemaleAdultMiddle AgedAdolescentYoung AdultChinaChildAgedBiomarkers, TumorImmunohistochemistryPeptide Fragments

Stichwörter der Autor:innen

MAGE‐A4NY‐ESO‐1cancer testis antigenimmunotherapysarcoma

Substanzen

Antigens, NeoplasmPRAME protein, humanMAGEA4 protein, humanCTAG1B protein, humanNeoplasm ProteinsMembrane ProteinsMelanoma-Specific AntigensMAGE-A1 protein (278-286), humanBiomarkers, TumorPeptide Fragments

Autor:innen und Institutionen

  • Nanjing University of Chinese Medicine, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
  • The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
  • Department of Pathology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.

ORCID-Profile: Rutian Li

Förderung

  • Youth project of Nanjing Medical Science and Technology Development Fund
  • Project supported by the Young Scientists Fund of the National Natural Science Foundation of China
  • Science Fund for Distinguished Young Scholars of Jiangsu Province
  • The Youth Fund Project of Natural Science Foundation of Jiangsu Province Basic Research Program
  • National Natural Science Foundation of China
  • Fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University

Zitieren

APA

Chen, A., Qiu, Y., Yen, Y. T., Wang, C., Wang, X., Li, C., Wei, Z., Li, L., Yu, L., Liu, F., & Li, R. (2025). Expression of Cancer‐Testis Antigens MAGE ‐ A1 , MAGE ‐ A4 , NY ‐ ESO ‐1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China. Cancer Medicine. https://doi.org/10.1002/cam4.70750

Vancouver

Chen A, Qiu Y, Yen YT, Wang C, Wang X, Li C, et al. Expression of Cancer‐Testis Antigens MAGE ‐ A1 , MAGE ‐ A4 , NY ‐ ESO ‐1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China. Cancer Medicine. 2025. doi:10.1002/cam4.70750

BibTeX
@article{Chen2025,
  author = {Chen, Anni and Qiu, Yuling and Yen, Ying-Tzu and Wang, Chun and Wang, Xiaolu and Li, Chunhua and Wei, Zijian and Li, Lin and Yu, Lixia and Liu, Fangcen and Li, Rutian},
  title = {Expression of Cancer‐Testis Antigens MAGE ‐ A1 , MAGE ‐ A4 , NY ‐ ESO ‐1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70750}
}
Kostenlos starten →